JP2025509955A - リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 - Google Patents

リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 Download PDF

Info

Publication number
JP2025509955A
JP2025509955A JP2024556125A JP2024556125A JP2025509955A JP 2025509955 A JP2025509955 A JP 2025509955A JP 2024556125 A JP2024556125 A JP 2024556125A JP 2024556125 A JP2024556125 A JP 2024556125A JP 2025509955 A JP2025509955 A JP 2025509955A
Authority
JP
Japan
Prior art keywords
sodium phosphate
hydrocortisone
pharmaceutical formulation
monothioglycerol
clause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509955A5 (cg-RX-API-DMAC7.html
Inventor
チェン，シャオミン
オング，シャオウェイ
Original Assignee
アンタレス・ファーマ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタレス・ファーマ・インコーポレーテッド filed Critical アンタレス・ファーマ・インコーポレーテッド
Publication of JP2025509955A publication Critical patent/JP2025509955A/ja
Publication of JP2025509955A5 publication Critical patent/JP2025509955A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024556125A 2022-03-21 2023-03-21 リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 Pending JP2025509955A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263321997P 2022-03-21 2022-03-21
US63/321,997 2022-03-21
US202263322934P 2022-03-23 2022-03-23
US63/322,934 2022-03-23
US202263387727P 2022-12-16 2022-12-16
US63/387,727 2022-12-16
PCT/US2023/064771 WO2023183807A1 (en) 2022-03-21 2023-03-21 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol

Publications (2)

Publication Number Publication Date
JP2025509955A true JP2025509955A (ja) 2025-04-11
JP2025509955A5 JP2025509955A5 (cg-RX-API-DMAC7.html) 2026-03-31

Family

ID=88102190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556125A Pending JP2025509955A (ja) 2022-03-21 2023-03-21 リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤

Country Status (5)

Country Link
US (3) US12102643B2 (cg-RX-API-DMAC7.html)
EP (1) EP4496575A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509955A (cg-RX-API-DMAC7.html)
CA (1) CA3246335A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023183807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496575A4 (en) * 2022-03-21 2026-04-01 Antares Pharma Inc AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2970944A (en) 1958-04-04 1961-02-07 Merck & Co Inc Parenteral solutions of steroid phosphates stabilized with creatinines
IL34366A (en) * 1969-05-07 1973-06-29 Lepetit Spa Stable aqueous 21-hydroxy steroid phosphate solutions
US5173488A (en) * 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
WO2006079064A1 (en) 2005-01-24 2006-07-27 Antares Pharma, Inc. Prefilled needle assisted jet injector
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
ES2548447T3 (es) 2008-03-10 2015-10-16 Antares Pharma, Inc. Dispositivo de seguridad para inyector
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
WO2014165142A1 (en) 2013-03-13 2014-10-09 Benjamin Newton Multiple dosage injector with rotating screw dosage system
EP3189855B1 (en) * 2016-01-11 2018-03-21 Lamda Laboratories S.A. Oral pharmaceutical solutions containing hydrocortisone sodium phosphate
FR3047904B1 (fr) 2016-02-18 2018-03-23 Crossject Dispositif d’injection sans aiguille a membrane coulissante
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
EP3787671A4 (en) 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
AU2021345429A1 (en) * 2020-09-21 2023-05-04 Antares Pharma, Inc. Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
FR3128874B1 (fr) * 2021-11-09 2025-04-18 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
EP4496575A4 (en) * 2022-03-21 2026-04-01 Antares Pharma Inc AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL

Also Published As

Publication number Publication date
EP4496575A1 (en) 2025-01-29
US12102643B2 (en) 2024-10-01
US20240238311A1 (en) 2024-07-18
US12521404B2 (en) 2026-01-13
WO2023183807A1 (en) 2023-09-28
US20230302016A1 (en) 2023-09-28
US20260091042A1 (en) 2026-04-02
EP4496575A4 (en) 2026-04-01
CA3246335A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US11857555B2 (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
KR20260047287A (ko) 간질 장애의 치료를 위한 방법 및 조성물
US20260091042A1 (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
JP6857647B2 (ja) クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US20150258104A1 (en) Use of noribogaine for the treatment of pain
JP2023052576A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
WO2016203497A1 (en) A ready-to-administer solution of fentanyl citrate
RU2709509C1 (ru) Режим дозирования для лечения острых обострений воспалительных состояний
AU2018388417B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
CN107961215B (zh) 一种左西替利嗪注射剂
RU2860343C2 (ru) Водный фармацевтический состав на основе гидрокортизона натрия фосфата и монотиоглицерина
WO2024062443A1 (en) Pharmaceutical compositions
EP3369422A1 (en) External preparation
WO2022178018A1 (en) Liquid unit dosage forms for treatment of pain
AU2005274875A1 (en) Methods and materials for treating mental illness
HK40089623A (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
US20090018106A1 (en) Intravenous formulations of pyridoxal 5'- phosphate and method of preparation
WO2026064400A1 (en) Steroid blockers of t-type calcium channels for treatment of pain
CA2603334A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323